(Q45356817)

English

Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets

scientific article published on 21 June 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

attenuated vaccine

1 reference

based on heuristic

inferred from title

canine distemper

1 reference

based on heuristic

inferred from title

Canine distemper virus

object named as

canine distemper virus

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

object named as

Martin Ludlow

2

0 references

Rik L. de Swart

object named as

Rik L de Swart

9

0 references

Geert van Amerongen

3

object named as

Geert van Amerongen

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

5

object named as

Selma Yüksel

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Rory D. de Vries

4

object named as

Rory D de Vries

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

author name string

D Tien Nguyen

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

R Joyce Verburgh

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

language of work or name

0 references

publication date

21 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

5073-5080

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Canine distemper virus--a morbillivirus in search of new hosts?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Pathogenesis and immunopathology of systemic and nervous canine distemper

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Development of a challenge-protective vaccine concept by modification of the viral RNA-dependent RNA polymerase of canine distemper virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Recombinant canine distemper virus strain Snyder Hill expressing green or red fluorescent proteins causes meningoencephalitis in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Efficient isolation of wild strains of canine distemper virus in Vero cells expressing canine SLAM (CD150) and their adaptability to marmoset B95a cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

TaqMan based real time PCR for the quantification of canine distemper virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Lipopeptide vaccines--yesterday, today, and tomorrow

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Age and long-term protective immunity in dogs and cats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Early target cells of measles virus after aerosol infection of non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Serum antibody decay in adults following natural respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.079

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.05.079

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45356817&oldid=2075583351"